<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456235</url>
  </required_header>
  <id_info>
    <org_study_id>I06024</org_study_id>
    <nct_id>NCT00456235</nct_id>
  </id_info>
  <brief_title>Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors</brief_title>
  <acronym>MONOCEPT</acronym>
  <official_title>Interruption of the Calcineurine Inhibitors (ICN) and Introduction of Mycophenolate Mofetil (MMF) in Liver Transplant Patients With Side Effects Due to ICN: Study of the Reduction of the Risks of Rejection by Mycophenolate Mofetil Therapeutic Drug Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <brief_summary>
    <textblock>
      The aim of this project is to determine whether, in liver transplant patients with side
      effects due to ICN, the use of MMF in monotherapy can be optimised by dose adjustment based
      on the area under the curve (AUC) of mycophenolic acid (MPA). It involves a multicentre phase
      IV trial with direct individual benefit.

      A population of 130 liver transplant patients at 2 to 10 years post-transplant, showing
      significant clinical ICN side effects and being given bitherapy by ICN +MMF will be included
      and randomised 1:1 in two arms:

        -  Arm 1: progressive interruption of ICN after obtaining an AUC of MPA of 50 mg.h/l,
           followed by MMF monotherapy with dose adjustment based on the AUC of MPA,

        -  Arm 2: continuation of the ICN+MMF bitherapy without MMF therapeutic drug monitoring.

      The main judgement criterion will be the incidence of acute rejection in the 2 groups at 6
      months. The secondary judgment criterion will be the evaluation of the benefit of stopping
      ICN on the side effects caused by these drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of biopsy proven acute rejection treated</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of biopsy proven acute rejection treated with corticoids or requiring a re-introduction of ICN in arm 1 -- or an increase of ICN in arm 2 -- 6 months after the interruption of ICN (arm 1) or after randomization (arm 2).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>adjument MMF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adjusting the dose according to the MMF AUC of mycophenolic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>continued treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continued treatment empirically usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophénolate Mofétil</intervention_name>
    <arm_group_label>adjument MMF</arm_group_label>
    <arm_group_label>continued treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporine A</intervention_name>
    <arm_group_label>adjument MMF</arm_group_label>
    <arm_group_label>continued treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <arm_group_label>adjument MMF</arm_group_label>
    <arm_group_label>continued treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with first liver transplantion or retransplantation since more than 6 months:
             with a post-transplant lapse of time of 2 to 10 years and showing one of the following
             adverse effects of ICN:

          -  Renal insufficiency defined by a creatinine clearance &lt;50ml/mn (calculated or
             estimated according to the Cockcroft formula)

          -  Arterial hypertension not controlled by an anti-hypertensive bitherapy

          -  Diabetes mellitus (fasting glycaemia &gt;7.0mmol/l), whether treated or not

          -  Neuromuscular toxicity

          -  Immunosuppression by cyclosporine or tacrolimus and MMF

          -  Hepatic biopsy performed within the 6 months preceding the inclusion for the patients
             with a post-transplant period of &lt;5 years and in the 12 months preceding the inclusion
             for patients with a post transplant period of &gt;5 years.

        Exclusion Criteria:

          -  Acute rejection within the 6 months preceding the screening

          -  Previous history of cortico-resistant rejection

          -  Chronic rejection

          -  Significant ductopenia (absence of inter-lobule biliary canals in more than 30% of the
             portal tracts) on the pre-screening biopsy.

          -  Existence of a pre-transplantation diabetes mellitus.

          -  Liver transplantation for auto-immune hepatitis or primary sclerosing cholangitis

          -  Patients transplanted for viral C cirrhosis with reinfection lesions of the
             transplanted organ, rendering treatment by ribarivine + interferon conceivable in the
             year following inclusion.

          -  Counter-indications to MMF (anaemia, leucopenia)

          -  Immunosuppression by sirolimus, everolimus, azathioprine or corticoids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre MARQUET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

